Clinical trial NCT00461149 - References

Acromegaly — Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly

Citation(s)

•   Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB
  Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab. 1998 Oct;83(10):3411-8.
•   American Diabetes Association
  Diagnosis and classification of diabetes mellitus. Diabetes Care. 2006 Jan;29 Suppl 1:S43-8.
•   Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS
  Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab. 2004 Apr;
•   Bates AS, Van't Hoff W, Jones JM, Clayton RN
  An audit of outcome of treatment in acromegaly. Q J Med. 1993 May;86(5):293-9.
•   Bevan JS
  Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab. 2005 Mar;90(3):1856-63. Epub 2004 Dec 21. Review.
•   Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G
  Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab. 2001 Jun;86(6):277
•   Colao A, Lombardi G
  Growth-hormone and prolactin excess. Lancet. 1998 Oct 31;352(9138):1455-61. Review.
•   Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, Salvatore M, Boerlin V, Lancranjan I, Lombardi G
  Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab. 2000 Sep;85(9):3132
•   Colao A, Pivonello R, Auriemma RS, Briganti F, Galdiero M, Tortora F, Caranci F, Cirillo S, Lombardi G
  Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Meta
•   Colao A, Pivonello R, Rosato F, Tita P, De Menis E, Barreca A, Ferrara R, Mainini F, Arosio M, Lombardi G
  First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospectiv
•   Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, Barausse M, Albizzi M, Dallabonzana D, Pedroncelli AM
  Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin En
•   Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P, Cortesi L, Pagani G
  Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tum
•   Etxabe J, Gaztambide S, Latorre P, Vazquez JA
  Acromegaly: an epidemiological study. J Endocrinol Invest. 1993 Mar;16(3):181-7.
•   Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D
  Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2005 Aug;90(8):4465-73. Epub 2005 May 10.
•   Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S
  Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab. 2000 Feb;85(2):526-9. Review.
•   Holdaway IM, Rajasoorya RC, Gamble GD
  Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004 Feb;89(2):667-74.
•   Kauppinen-Mäkelin R, Sane T, Reunanen A, Välimäki MJ, Niskanen L, Markkanen H, Löyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P, Salmela P, Salmi J, Stenman UH, Viikari J, Voutilainen E
  A nationwide survey of mortality in acromegaly. J Clin Endoc
•   Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC
  Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985 Jul;28(7):412-9.
•   Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D, Barkan A
  A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab. 2005 Jul;90(7):4405-10. Epub
•   Orme SM, McNally RJ, Cartwright RA, Belchetz PE
  Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab. 1998 Aug;83(8):2730-4.
•   Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK
  Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf). 1994 Jul;41(1):95-102.
•   Swearingen B, Barker FG 2nd, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT
  Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab. 1998 Oct;83(10):3419-26.
•   Turner HE, Vadivale A, Keenan J, Wass JA
  A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clin Endocrinol (Oxf). 1999 Sep;51(3):275-80.
•   Wright AD, Hill DM, Lowy C, Fraser TR
  Mortality in acromegaly. Q J Med. 1970 Jan;39(153):1-16.

Beneficial Effect of Dose Escalation of Octreotide-LAR as First-Line Therapy in Patients With Resistant Acromegaly

Details for clinical trial NCT00461149